These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20068074)

  • 1. Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells.
    Rasool N; LaRochelle W; Zhong H; Ara G; Cohen J; Kohn EC
    Clin Cancer Res; 2010 Jan; 16(2):600-9. PubMed ID: 20068074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells.
    Simpkins FA; Devoogdt NM; Rasool N; Tchabo NE; Alejandro EU; Kamrava MM; Kohn EC
    Carcinogenesis; 2008 Mar; 29(3):466-72. PubMed ID: 17916899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.
    Devoogdt N; Rasool N; Hoskins E; Simpkins F; Tchabo N; Kohn EC
    Cancer Sci; 2009 Mar; 100(3):434-40. PubMed ID: 19154415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells.
    Belotti D; Rieppi M; Nicoletti MI; Casazza AM; Fojo T; Taraboletti G; Giavazzi R
    Clin Cancer Res; 1996 Oct; 2(10):1725-30. PubMed ID: 9816123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
    Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
    Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
    Guo Y; Nemeth J; O'Brien C; Susa M; Liu X; Zhang Z; Choy E; Mankin H; Hornicek F; Duan Z
    Clin Cancer Res; 2010 Dec; 16(23):5759-69. PubMed ID: 20699329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.
    Huang L; Ao Q; Zhang Q; Yang X; Xing H; Li F; Chen G; Zhou J; Wang S; Xu G; Meng L; Lu Y; Ma D
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):447-56. PubMed ID: 19760195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
    Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
    BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells.
    Hoskins E; Rodriguez-Canales J; Hewitt SM; Elmasri W; Han J; Han S; Davidson B; Kohn EC
    Gynecol Oncol; 2011 Sep; 122(3):656-62. PubMed ID: 21676452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
    Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
    Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.
    Barker SD; Coolidge CJ; Kanerva A; Hakkarainen T; Yamamoto M; Liu B; Rivera AA; Bhoola SM; Barnes MN; Alvarez RD; Curiel DT; Hemminki A
    J Gene Med; 2003 Apr; 5(4):300-10. PubMed ID: 12692864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
    Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
    Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
    PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.
    Kang Y; Hu W; Ivan C; Dalton HJ; Miyake T; Pecot CV; Zand B; Liu T; Huang J; Jennings NB; Rupaimoole R; Taylor M; Pradeep S; Wu SY; Lu C; Wen Y; Huang J; Liu J; Sood AK
    J Natl Cancer Inst; 2013 Oct; 105(19):1485-95. PubMed ID: 24062525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis.
    Mo Q; Zhang Y; Jin X; Gao Y; Wu Y; Hao X; Gao Q; Chen P
    Tumour Biol; 2016 Nov; 37(11):14745-14755. PubMed ID: 27629142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
    Wang X; Wu E; Wu J; Wang TL; Hsieh HP; Liu X
    PLoS One; 2013; 8(6):e65686. PubMed ID: 23762410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
    Sun NK; Huang SL; Chang TC; Chao CC
    J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.